National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 7) (PB 70 of 2016) (Cth)

PB 70 of 2016

National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 7)

National Health Act 1953

I, DIANNA PROSSER, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated    25^th   July 2016

DIANNA PROSSER

Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

Part 1         Preliminary

1. Name of Determination

   (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 7).

   (2)   This Determination may also be cited as PB 70 of 2016.

2. Commencement

   This Determination commences on 1 August 2016.

3. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

   Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Asenapine

Omit

Atomoxetine

[2]     Schedule 1, after item dealing with Folic acid

Omit

Follitropin Alfa

[3]     Schedule 1, after item dealing with Tapentadol

Omit

Telbivudine

[4]     Schedule 1, after item dealing with Tipranavir

Omit

Tobramycin

[5]     Schedule 2, after item dealing with Atenolol

Insert

Atomoxetine

[6]     Schedule 2, after item dealing with Folinic acid

Insert

Follitropin Alfa

[7]     Schedule 2, after item dealing with Tirofiban

Insert

Tobramycin